Supplementary Figures
Superposition of unbound activated MARTX Vc CPD (red) 10 and inhibitor-bound activated MARTX Vc CPD (blue) (root-mean-square-deviation of 0.5 Å). Electron density around the Leu epoxide inhibitor is contoured at 1.5 σ.
Supplementary Fig. 4
Supplementary Figure 4 Activation of P. luminescens MARTX CPD autocleavage by InsP 6 . Cleavage of MARTX Vc , particularly at Leu2447, activates the actin crosslinking activity of the ACD.
Supplementary Figure 7
Comparison of the Cys-His catalytic dyad and active site topology of MARTX Vc CPD (aa 3391-3650) to the active sites of caspase-3 (PDB ID 2C1E) 12 and P.
gingivalis gingipain R (PDB ID 1CVR) 13 . were used to amplify a 5' fragment comprising the ACD domain, and primers #08 and #04 were used to amplify a 3' fragment comprising the RID domain. The resulting fragments were used as the templates for a second PCR reaction using the flanking primers, #01 and #04, to amplify an ACD-RID fragment carrying the L2447A mutation.
Supplementary
To construct strains expressing His 6 -tagged V. vulnificus MARTX CPD, primers #20 and #21 were used to amplify DNA encoding residues 4044-4299 of VV20479 from V.
vulnificus CMCP6 genomic DNA (P. Gulig). The catalytic Cys mutation was introduced by PCR SOE using internal SOE primers #22 and #23. To construct strains expressing His 6 -tagged P. luminescens MARTX CPDs, primer pairs #24 and #25, #30 and #31, #34
and #35, and #36 and #37, were used to amplify DNA encoding residues 2390-2630 of Plu3217, residues 2369-2636 of Plu3324, residues 2524-2775 of Plu1341, and residues 2902-3173 of Plu1344, respectively. The catalytic Cys and L2408 cleavage site mutations for Plu3217 were introduced using PCR SOE primer pairs #26 and #27; and #28 and #29, respectively. The catalytic Cys mutation for Plu3324 was introduced by PCR SOE using primer pair #32 and #33, and the catalytic Cys mutation for Plu1341 was introduced by PCR SOE using primer pair #36 and #37.
For all His 6 -tagged constructs, the procedures described for pET28a-ACD were followed, with the exception that some sequences were cloned into the pET22b expression vector.
To construct point mutations in V. cholerae, double homologous recombination using the sacB-lethality counterselection method was used 2 . In general, ~0.5-0.6 kB of sequence flanking the point mutation or region to be deleted was amplified and then fused together in a second reaction using PCR SOE. For the L2447A mutant, the flanking primers were #40 and #41, while the internal SOE primers were #08 and #09. For the L3099A mutant, the flanking primers were #42 and #43, and the internal SOE primers were #16 and #17.
For the L3441A mutant, the flanking primers were #44 and #45, and the internal SOE primers were #18 and #19. SOE PCR fragments were ligated into the sucrose-based counter selectable plasmid pGP704-Sac28 using the NcoI/XbaI sites for the L3099A and L3441A vectors and NcoI/AgeI for the L2447A vector 3 . Allelic exchange plasmids were transformed into E. coli SM10λpir and mated into the recipient V. cholerae strain.
Consistent with previous studies of V. cholerae MARTX function, the V. cholerae N19691 strain referred to as wildtype contains an in-frame deletion in hapA to reduce heterologous proteolysis of MARTX Vc in culture supernatants [4] [5] [6] [7] . Sucrose-based counter selection was done essentially as described 5 , and mutations were confirmed by PCR or genomic DNA sequencing. To construct the V. cholerae L2447A/L3099A strain, E. coli strain AS192 was conjugated to V. cholerae strain AS179 (L2447A). To construct the double mutants L2447A/L3441A and L3099A/L3441A, E. coli strain AS208 was conjugated to V. cholerae strains AS179 (L2447A) and AS187 (L3099A), respectively.
The triple mutant (3X) was constructed by conjugating E. coli strain AS208 to V. cholerae strain AS200 (L2447A/L3099A).
Crystallization and data collection
The CPD core domain (residues 3391-3650) was concentrated to 1 mM and mixed with a 2-fold excess (2 mM) of InsP 6 and JCP598 for crystallization. Diffraction quality crystals were grown in 0.5 μL sitting drops in an equal volume of 100 mM Tris-HCl pH 8.5, 30% PEG 3350 and 15% MPD at 22ºC.
Crystals were cryoprotected in the mother liquor and data was collected at 100K under cryo-cooled conditions at a wavelength of 1.0 Å at the Stanford Synchrotron Radiation Laboratory (beamline 11-1). Diffraction data was processed using HKL2000 8 , and R meas was calculated using SCALA 9 . Data processing statistics are listed in Supplementary   Table 1. A note on inhibitor analyses Although the CPD inhibitors blocked MARTX Vc toxin activation, they failed to irreversibly inhibit CPD protease activity in our biochemical analyses. In the inhibitor structure, however, JCP598 was irreversibly bound to the catalytic Cys of activated CPD (Fig. 2) . The unique activation mechanism of the CPD likely explains these seemingly incongruous results. Due to its allosteric activation mechanism, the CPD active site is only accessible to general alkylating agents and substrates when the protease is bound to InsP 6 ; furthermore, InsP 6 exhibits rapid on-offbinding kinetics for the CPD 10 . Thus, under normal assay conditions, our CPD inhibitors only transiently occupy the protease active site; as a result, the CPD catalytic Cys does not have sufficient time to react with the reactive electrophile of the inhibitor. In contrast, in the protein crystal, the protease is locked in an activated conformation such that the catalytic Cys is constitutively available to alkylate the inhibitor. These observations suggest that, rather than targeting the active site, a more effective class of CPD inhibitors might target the InsP 6 binding site or interfere with the structural transition induced by 
